Illumina Inc. has announced the launch of Illumina Protein Prep, an assay designed to enhance next-generation sequencing-based proteomics discovery at scale. Previously available through an early-access program, Illumina Protein Prep is now accessible to customers worldwide. The assay enables researchers to integrate proteomics into large-scale genomics studies, providing a streamlined sample-to-insights solution for discovery and clinical research in areas such as cancer, cardio metabolic, and immunologic diseases. Illumina Protein Prep is capable of measuring 9,500 unique human protein targets, offering new insights into protein biology to support novel disease treatment discoveries. The launch follows Illumina's agreement to acquire SomaLogic, further advancing the company's presence in the proteomics market. No specific results were presented with the announcement.